Trazocalm – For the appointments that make everyone sweat

Trazocalm® – For the appointments that make everyone sweat.

Managing canine stress and anxiety during vet visits and supporting confinement compliance following surgery remains one of the most persistent challenges in small animal practice. From orthopaedic recoveries to routine examinations, stress-related behaviours can compromise healing, client compliance, and the safety of veterinary teams. With animal bites reported by more than half of veterinarians and over 60% of veterinary nurses and technicians in the past year¹, the need for effective, reliable solutions has never been clearer.

Veterinarians now have access to APVMA-approved^* Trazodone designed specifically for use in clinic. Trazocalm®, a veterinary first that brings regulatory oversight, flexible dosing, and proven outcomes together in one product.

Trazocalm® for supporting post-operative recovery

It’s no secret that confinement following orthopaedic surgery is essential for recovery - but often difficult for both dogs and their owners. Failure to comply with activity restriction may lead to protracted recovery or even surgical treatment failure. Clinical studies show that 89% of clients rate trazodone as moderately or extremely helpful in improving confinement tolerance and calmness during recovery².

Trazocalm is indicated for post-operative confinement in dogs, with a starting dose of 3.5 mg/kg and flexible titration up to 7–10 mg/kg, administered for a minimum of four weeks. Importantly, it is well tolerated alongside common pain medications, facilitates confinement and enhances behavioural calmness of dogs during the critical recovery period following orthopaedic surgery.

Trazocalm® for reducing stress & anxiety in clinics during veterinary care

Stress during veterinary visits is not only distressing for dogs but can also hinder examinations, diagnostics, and handling. Signs such as panting, lip licking, trembling, and vocalisation are familiar to every veterinary professional. Trazocalm® helps reduce these behavioural signs of fear, with quick effects often beginning within 30–45 minutes of administration³.

For situational anxiety associated with transport, examinations, or hospital visits, Trazocalm® can be given approximately 90 minutes prior, using a starting dose of 3.5 mg/kg and a maximum dose of 9–12 mg/kg. This predictable onset supports higher-quality clinical examinations and improved patient welfare.

Designed for real-world veterinary use

Trazocalm® is available in three strengths; 50 mg, 100 mg, and 150 mg, featuring trisect and half-scored tablets to allow precise, flexible dosing across a wide range of canine sizes. Supplied in cost-effective 100-tablet bottles, it is designed to integrate seamlessly into everyday prescribing and is readily available from your preferred wholesaler.

Trazocalm® is APVMA-approved* under a permit.  Approval involves rigorous assessment of a product against safety and efficacy criteria and unlike compounded products an adverse event reporting system is in place for approved products. The AVA’s policy on use of compounded pharmaceuticals recommends use of registered products or products administered under an APVMA permit, where suitable, in preference to compounded products. Refer to the AVA’s veterinary use of compounded pharmaceuticals. ⁴

Refer Agricultural And Veterinary Permits Search - portal.apvma.gov.au

Innovation with purpose

Proudly brought to market by InVetro, an Australian veterinary pharmaceutical company, Trazocalm® reflects a commitment to innovation, safety, and practical solutions that support veterinary teams and improve patient care.

As practices continue to prioritise low-stress handling, compliant recovery, and team safety, Trazocalm® offers a calm, confident step forward - improving welfare for canine patients, and supporting their caregivers, and the professionals dedicated to their care.

For more information contact InVetro info@invetro.com.au | 02 8067 8354.

References

^* Trazocalm® is a veterinary medicine approved under APVMA permit PER93844. This permit authorises supply of an unregistered product. An application has been made to register the product.
¹ Johnson, L. and Fritschi, L. (2024) ‘Frequency of workplace incidents and injuries in veterinarians, veterinary nurses and veterinary students and measures to control these’, Australian Veterinary Journal, 102(9), pp. 431–439. doi:10.1111/avj.13354.
² Gruen M et al. Use of trazodone to facilitate postsurgical confinement in dogs. Journal AVMA. 2014 Aug;245(3):296-301
³ Kim et al. Effects of trazodone on behavioral and physiological signs of stress in dogs during veterinary visits. Journal AVMA. 2022 Mar 24;260(8):876-883.
⁴ Australian Veterinary Association. Veterinary use of compounded pharmaceuticals policy. Compounded products should only be used where no suitable registered product is available. Available at: AVA policy on compounded pharmaceuticals.